| NCT07006805 | RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis | NOT_YET_RECRUITING | PHASE1, PHASE2 | 2025-08 | 2029-10 | 2028-09 |
| NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING | PHASE1, PHASE2 | 2024-12-17 | 2029-09 | 2029-09 |
| NCT06328777 | RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis | RECRUITING | PHASE1, PHASE2 | 2024-07-02 | 2029-07 | 2029-07 |
| NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING | PHASE1, PHASE2 | 2024-02-16 | 2027-12 | 2027-12 |
| NCT06154252 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | RECRUITING | PHASE1, PHASE2 | 2023-12-20 | 2028-07 | 2028-07 |
| NCT05451212 | Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis | RECRUITING | PHASE1 | 2022-11-23 | 2028-10 | 2028-10 |
| NCT04422912 | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) | RECRUITING | PHASE1 | 2020-09-29 | 2029-01 | 2029-01 |